One of the world’s largest studies of Ozempic, Mounjaro and other blockbuster diabetes and obesity drugs highlighted their ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we ...

While we’re unlikely to see a dramatic rise in deaths from vaccine-preventable diseases in the U.S. in the near term, the ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

and in a phase 1 study achieved clinically significant body weight reductions over 12 weeks in people with obesity and without diabetes, according to Amgen. The drug was given as a subcutaneous ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.